PROM1 and glioblastoma: Consequently, using a large-scale proteomic panel derived from patients with pathology-proven GBM, this analysis demonstrated that CD133 can be effectively measured in serum, enabling the investigation of its potential utility and associations with other markers and survival outcomes.